Products
PER-001 | Perfuse Therapeutics
Product description
A first-in-class small molecule endothelin antagonist in a sustained-release intravitreal implant designed to improve retinal blood flow and prevent the death of retinal cells caused by the upregulation of endogenous endothelin.